Toll-like receptor modulation in cardiovascular disease: a target for intervention?

Bibliography

• LEMAITRE B, NICOLAS E, MICHAUT L, REICHHART JM, HOFFMANN JA: The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell (1996) 86:973-983.
   PubMed Web of Science ®Google Scholar
• JANEWAY CA Jr, MEDZHITOV R: Innate immune recognition. Ann. Rev. Immunol. (2002) 20:197-216.
   PubMed Web of Science ®Google Scholar
• TAKEDA K, KAISHO T, AKIRA S: Toll-like receptors. Ann. Rev. Immunol. (2003) 21:335-376.
   PubMed Web of Science ®Google Scholar
• ZHANG D, ZHANG G, HAYDEN MS et al.: A toll-like receptor that prevents infection by uropathogenic bacteria. Science (2004) 303:1522-1526.
   PubMed Web of Science ®Google Scholar
• DIVANOVIC S, TROMPETTE A, ATABANI SF et al.: Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat. Immunol. (2005) 6:571-578.
   PubMed Web of Science ®Google Scholar
• AKIRA S, TAKEDA K, KAISHO T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. (2001) 2:675-680.
   PubMed Web of Science ®Google Scholar
• JANSSENS S, BEYAERT R: Role of Toll-like receptors in pathogen recognition. Clin. Microbiol. Rev. (2003) 16:637-646.
   PubMed Web of Science ®Google Scholar
• AHMAD-NEJAD P, HACKER H, RUTZ M et al.: Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. (2002) 32:1958-1968.
   PubMed Web of Science ®Google Scholar
• HEIL F, HEMMI H, HOCHREIN H et al.: Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 303:1526-1529.
   PubMed Web of Science ®Google Scholar
• AKIRA S, UEMATSU S, TAKEUCHI O: Pathogen recognition and innate immunity. Cell (2006) 124:783-801.
   PubMed Web of Science ®Google Scholar
• HAYASHI F, SMITH KD, OZINSKY A et al.: The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature (2001) 410:1099-1103.
   PubMed Web of Science ®Google Scholar
• MEDZHITOV R, PRESTON-HURLBURT P, JANEWAY CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature (1997) 388:394-397.
   PubMed Web of Science ®Google Scholar
• HEMMI H, TAKEUCHI O, KAWAI T et al.: A Toll-like receptor recognizes bacterial DNA. Nature (2000) 408:740-745.
   PubMed Web of Science ®Google Scholar
• HEINE H, LIEN E: Toll-like receptors and their function in innate and adaptive immunity. Int. Arch. Allergy Immunol. (2003) 130:180-192.
   PubMed Web of Science ®Google Scholar
• BEG AA: Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol. (2002) 23:509-512.
   PubMed Web of Science ®Google Scholar
• SMILEY ST, KING JA, HANCOCK WW: Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J. Immunol. (2001) 167:2887-2894.
   PubMedGoogle Scholar
• WALLIN RP, LUNDQVIST A, MORE SH et al.: Heat-shock proteins as activators of the innate immune system. Trends Immunol. (2002) 23:130-135.
   PubMed Web of Science ®Google Scholar
• FRANTZ S, KELLY RA, BOURCIER T: Role of TLR-2 in the activation of nuclear factor κB by oxidative stress in cardiac myocytes. J. Biol. Chem. (2001) 276:5197-5203.
   PubMed Web of Science ®Google Scholar
• JOHNSON GB, BRUNN GJ, TANG AH, PLATT JL: Evolutionary clues to the functions of the Toll-like family as surveillance receptors. Trends Immunol. (2003) 24:19-24.
   PubMed Web of Science ®Google Scholar
• AXTELLE T, PRIBBLE J: IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. J. Endotoxin. Res. (2001) 7:310-314.
   PubMedGoogle Scholar
• DUNNE A, O’NEILL LA: Adaptor usage and Toll-like receptor signaling specificity. FEBS Lett. (2005) 579:3330-3335.
   PubMed Web of Science ®Google Scholar
• AKIRA S, TAKEDA K: Toll-like receptor signalling. Nat. Rev. Immunol. (2004) 4:499-511.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO M, SATO S, HEMMI H et al.: Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science (2003) 301:640-643.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO M, SATO S, HEMMI H et al.: TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat. Immunol. (2003) 4:1144-1150.
   PubMed Web of Science ®Google Scholar
• BIN LH, XU LG, SHU HB: TIRP, a novel Toll/interleukin-1 receptor (TIR) domain-containing adapter protein involved in TIR signaling. J. Biol. Chem. (2003) 278:24526-24532.
   PubMed Web of Science ®Google Scholar
• COOK DN, PISETSKY DS, SCHWARTZ DA: Toll-like receptors in the pathogenesis of human disease. Nat. Immunol. (2004) 5:975-979.
   PubMed Web of Science ®Google Scholar
• IWASAKI A, MEDZHITOV R: Toll-like receptor control of the adaptive immune responses. Nat. Immunol. (2004) 5:987-995.
   PubMed Web of Science ®Google Scholar
• MEDZHITOV R: Toll-like receptors and innate immunity. Nat. Rev. Immunol. (2001) 1:135-145.
   PubMed Web of Science ®Google Scholar
• NAPOLITANI G, RINALDI A, BERTONI F, SALLUSTO F, LANZAVECCHIA A: Selected Toll-like receptor agonist combinations synergistically trigger a T helper Type 1-polarizing program in dendritic cells. Nat. Immunol. (2005) 6:769-776.
   PubMed Web of Science ®Google Scholar
• BAUMGARTEN G, KNUEFERMANN P, NOZAKI N et al.: In vivo expression of proinflammatory mediators in the adult heart after endotoxin administration: the role of toll-like receptor-4. J. Infect. Dis. (2001) 183:1617-1624.
   PubMed Web of Science ®Google Scholar
• HOFFMANN JA, KAFATOS FC, JANEWAY CA, EZEKOWITZ RA: Phylogenetic perspectives in innate immunity. Science (1999) 284:1313-1318.
   PubMed Web of Science ®Google Scholar
• ANKER SD, VON HAEHLING S: Inflammatory mediators in chronic heart failure: an overview. Heart (2004) 90:464-470.
   PubMed Web of Science ®Google Scholar
• KNUEFERMANN P, VALLEJO J, MANN DL: The role of innate immune responses in the heart in health and disease. Trends Cardiovasc. Med. (2004) 14:1-7.
   PubMed Web of Science ®Google Scholar
• VISINTIN A, MAZZONI A, SPITZER JH et al.: Regulation of Toll-like receptors in human monocytes and dendritic cells. J. Immunol. (2001) 166:249-255.
   PubMed Web of Science ®Google Scholar
• ZAREMBER KA, GODOWSKI PJ: Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J.Immunol. (2002) 168:554-561.
   Google Scholar
• ALIPRANTIS AO, YANG RB, WEISS DS, GODOWSKI P, ZYCHLINSKY A: The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J. (2000) 19:3325-3336.
   PubMed Web of Science ®Google Scholar
• SHISHIDO T, NOZAKI N, YAMAGUCHI S et al.: Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation (2003) 108:2905-2910.
   PubMed Web of Science ®Google Scholar
• NOZAKI N, SHISHIDO T, TAKEISHI Y, KUBOTA I: Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation (2004) 110:2869-2874.
   PubMed Web of Science ®Google Scholar
• CHOW JC, YOUNG DW, GOLENBOCK DT, CHRIST WJ, GUSOVSKY F: Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem. (1999) 274:10689-10692.
   PubMed Web of Science ®Google Scholar
• HOSHINO K, TAKEUCHI O, KAWAI T et al.: Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. (1999) 162:3749-3752.
   PubMed Web of Science ®Google Scholar
• NEMOTO S, VALLEJO JG, KNUEFERMANN P et al.: Escherichia coli LPS-induced LV dysfunction: role of toll-like receptor-4 in the adult heart. Am. J. Physiol. Heart Circ. Physiol. (2002) 282:H2316-H2323.
   PubMed Web of Science ®Google Scholar
• ARBOUR NC, LORENZ E, SCHUTTE BC et al.: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. (2000) 25:187-191.
   PubMed Web of Science ®Google Scholar
• SALEH M, VAILLANCOURT JP, GRAHAM RK et al.: Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature (2004) 429:75-79.
   PubMed Web of Science ®Google Scholar
• SCHRODER NW, SCHUMANN RR: Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect. Dis. (2005) 5:156-164.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ DA, COOK DN: Polymorphisms of the Toll-like receptors and human disease. Clin. Infect. Dis. (2005) 41(Suppl. 7):S403-S407.
   PubMed Web of Science ®Google Scholar
• KIECHL S, LORENZ E, REINDL M et al.: Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. (2002) 347:185-192.
   PubMed Web of Science ®Google Scholar
• MURRAY CJ, LAUER JA, HUTUBESSY RC et al.: Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet (2003) 361:717-725.
   PubMed Web of Science ®Google Scholar
• LIBBY P: Inflammation in atherosclerosis. Nature (2002) 420:868-874.
   PubMed Web of Science ®Google Scholar
• BJORKBACKA H, KUNJATHOOR VV, MOORE KJ et al.: Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med. (2004) 10:416-421.
   PubMed Web of Science ®Google Scholar
• LEINONEN M, SAIKKU P: Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect. Dis. (2002) 2:11-17.
   PubMed Web of Science ®Google Scholar
• DUNZENDORFER S, LEE HK, SOLDAU K, TOBIAS PS: Toll-like receptor 4 functions intracellularly in human coronary artery endothelial cells: roles of LBP and sCD14 in mediating LPS responses. FASEB J. (2004) 18:1117-1119.
   PubMed Web of Science ®Google Scholar
• AMEZIANE N, BEILLAT T, VERPILLAT P et al.: Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler. Thromb. Vasc. Biol. (2003) 23:e61-e64.
   PubMed Web of Science ®Google Scholar
• BOEKHOLDT SM, AGEMA WR, PETERS RJ et al.: Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation (2003) 107:2416-2421.
   PubMed Web of Science ®Google Scholar
• LIN YC, CHANG YM, YU JM et al.: Toll-like receptor 4 gene C119A but not Asp299Gly polymorphism is associated with ischemic stroke among ethnic Chinese in Taiwan. Atherosclerosis (2005) 180:305-309.
   PubMed Web of Science ®Google Scholar
• XU XH, SHAH PK, FAURE E et al.: Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation (2001) 104:3103-3108.
   PubMed Web of Science ®Google Scholar
• VINK A, SCHONEVELD AH, VAN DER MEER JJ et al.: In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation (2002) 106:1985-1990.
   PubMed Web of Science ®Google Scholar
• FUSTER V, MORENO PR, FAYAD ZA, CORTI R, BADIMON JJ: Atherothrombosis and high-risk plaque: part I: evolving concepts. J. Am. Coll. Cardiol. (2005) 46:937-954.
   PubMed Web of Science ®Google Scholar
• HOLLESTELLE SC, DE VRIES MR, VAN KEULEN JK et al.: Toll-like receptor 4 is involved in outward arterial remodeling. Circulation (2004) 109:393-398.
   PubMed Web of Science ®Google Scholar
• METHE H, KIM JO, KOFLER S et al.: Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation (2005) 111:2654-2661.
   PubMed Web of Science ®Google Scholar
• SATOH M, SHIMODA Y, MAESAWA C et al.: Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. Int. J. Cardiol. (2006) 109(2):226-234.
   PubMed Web of Science ®Google Scholar
• EDFELDT K, SWEDENBORG J, HANSSON GK, YAN ZQ: Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation (2002) 105:1158-1161.
   PubMed Web of Science ®Google Scholar
• MULLICK AE, TOBIAS PS, CURTISS LK: Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest (2005) 115:3149-3156.
   PubMed Web of Science ®Google Scholar
• LEHR HA, SAGBAN TA, IHLING C et al.: Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation (2001) 104:914-920.
   PubMed Web of Science ®Google Scholar
• LEVY MM, FINK MP, MARSHALL JC et al.: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. (2003) 29:530-538.
   PubMedGoogle Scholar
• LEFER AM: Mechanisms of cardiodepression in endotoxin shock. Circ. Shock Suppl. (1979) 1:1-8.
   PubMedGoogle Scholar
• OGNIBENE FP, PARKER MM, NATANSON C, SHELHAMER JH, PARRILLO JE: Depressed left ventricular performance. Response to volume infusion in patients with sepsis and septic shock. Chest (1988) 93:903-910.
   PubMed Web of Science ®Google Scholar
• SASU S, LAVERDA D, QURESHI N, GOLENBOCK DT, BEASLEY D: Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ. Res. (2001) 89:244-250.
   PubMed Web of Science ®Google Scholar
• POLDERMAN KH, GIRBES AR: Drug intervention trials in sepsis: divergent results. Lancet (2004) 363:1721-1723.
   PubMed Web of Science ®Google Scholar
• RAEBURN CD, CALKINS CM, ZIMMERMAN MA et al.: Vascular cell adhesion molecule-1 expression is obligatory for endotoxin-induced myocardial neutrophil accumulation and contractile dysfunction. Surgery (2001) 130:319-325.
   PubMed Web of Science ®Google Scholar
• RUBIN LJ, KELLER RS, PARKER JL, ADAMS HR: Contractile dysfunction of ventricular myocytes isolated from endotoxemic guinea pigs. Shock (1994) 2:113-120.
   PubMed Web of Science ®Google Scholar
• BEUTLER B: TLR4 as the mammalian endotoxin sensor. Curr. Top. Microbiol. Immunol. (2002) 270:109-120.
   PubMed Web of Science ®Google Scholar
• SCHRODER NW, HERMANN C, HAMANN L et al.: High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 gene detected by a novel allele-specific PCR. J. Mol. Med. (2003) 81:368-372.
   PubMed Web of Science ®Google Scholar
• SATOH M, NAKAMURA M, AKATSU T et al.: Expression of Toll-like receptor 4 is associated with enteroviral replication in human myocarditis. Clin. Sci. (Lond.) (2003) 104:577-584.
   PubMed Web of Science ®Google Scholar
• MARTY RR, DIRNHOFER S, MAUERMANN N et al.: MyD88 signaling controls autoimmune myocarditis induction. Circulation (2006) 113:258-265.
   PubMed Web of Science ®Google Scholar
• TRIANTAFILOU K, ORTHOPOULOS G, VAKAKIS E et al.: Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent. Cell Microbiol. (2005) 7:1117-1126.
   PubMed Web of Science ®Google Scholar
• McMURRAY JJ, STEWART S: Epidemiology, aetiology, and prognosis of heart failure. Heart (2000) 83:596-602.
   PubMed Web of Science ®Google Scholar
• ANKER SD, VON HAEHLING S: Inflammatory mediators in chronic heart failure: an overview. Heart (2004) 90:464-470.
   PubMed Web of Science ®Google Scholar
• FRANTZ S, KOBZIK L, KIM YD et al.: Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J. Clin. Invest. (1999) 104:271-280.
   PubMed Web of Science ®Google Scholar
• NIEBAUER J, VOLK HD, KEMP M et al.: Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet (1999) 353:1838-1842.
   PubMed Web of Science ®Google Scholar
• BIRKS EJ, FELKIN LE, BANNER NR et al.: Increased toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J. Heart Lung Transplant. (2004) 23:228-235.
   PubMed Web of Science ®Google Scholar
• TORRE-AMIONE G, KAPADIA S, BENEDICT C et al.: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. (1996) 27:1201-1206.
   PubMed Web of Science ®Google Scholar
• ROSSIGNOL DP, LYNN M: Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J. Endotoxin. Res. (2002) 8:483-488.
   PubMedGoogle Scholar
• ROSSIGNOL DP, WASAN KM, CHOO E et al.: Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob. Agents Chemother. (2004) 48:3233-3240.
   PubMed Web of Science ®Google Scholar
• LYNN M, ROSSIGNOL DP, WHEELER JL et al.: Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J. Infect. Dis. (2003) 187:631-639.
   PubMed Web of Science ®Google Scholar
• LYNN M, WONG YN, WHEELER JL et al.: Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia. J. Pharmacol. Exp. Ther. (2004) 308:175-181.
   PubMed Web of Science ®Google Scholar
• WASAN KM, SIVAK O, COTE RA et al.: Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations. Antimicrob. Agents Chemother. (2003) 47:2796-2803.
   PubMed Web of Science ®Google Scholar
• YAMADA M, ICHIKAWA T, II M et al.: Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex- 1-ene-1-carboxylate. J. Med. Chem. (2005) 48:7457-7467.
   PubMed Web of Science ®Google Scholar
• CLUFF CW, BALDRIDGE JR, STOVER AG et al.: Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect. Immun. (2005) 73:3044-3052.
   PubMed Web of Science ®Google Scholar
• HAWKINS LD, ISHIZAKA ST, McGUINNESS P et al.: A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity. J. Pharmacol. Exp. Ther. (2002) 300:655-661.
   PubMed Web of Science ®Google Scholar
• DA SILVA CJ, SOLDAU K, CHRISTEN U, TOBIAS PS, ULEVITCH RJ: Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2. J. Biol. Chem. (2001) 276:21129-21135.
   PubMed Web of Science ®Google Scholar
• YANG RB, MARK MR, GRAY A et al.: Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature (1998) 395:284-288.
   PubMed Web of Science ®Google Scholar
• VERBON A, DEKKERS PE, TEN HOVE T et al.: IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J. Immunol. (2001) 166:3599-3605.
   PubMed Web of Science ®Google Scholar
• GENTH-ZOTZ S, VON HAEHLING S, BOLGER AP et al.: The anti-CD14 antibody IC14 suppresses ex vivo endotoxin stimulated tumor necrosis factor-α in patients with chronic heart failure. Eur. J. Heart Fail. (2005).
   Google Scholar
• REINHART K, GLUCK T, LIGTENBERG J et al.: CD14 receptor occupancy in severe sepsis: results of a Phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit. Care Med. (2004) 32:1100-1108.
   PubMed Web of Science ®Google Scholar
• BUWITT-BECKMANN U, HEINE H, WIESMULLER KH et al.: Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur. J. Immunol. (2005) 35:282-289.
   PubMed Web of Science ®Google Scholar
• VON HAEHLING S, ANKER SD: Future prospects of anticytokine therapy in chronic heart failure. Expert. Opin. Investig. Drugs (2005) 14:163-176.
   PubMed Web of Science ®Google Scholar
• VON HAEHLING S, ANKER SD, BASSENGE E: Statins and the role of nitric oxide in chronic heart failure. Heart Fail. Rev. (2003) 8:99-106.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, CANNON CP, MORROW D et al.: C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. (2005) 352:20-28.
   PubMed Web of Science ®Google Scholar
• NODE K, FUJITA M, KITAKAZE M, HORI M, LIAO JK: Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation (2003) 108:839-843.
   PubMed Web of Science ®Google Scholar
• FOLDES G, VON HAEHLING S, OKONKO DO, JANKOWSKA EA, POOLE-WILSON PA, ANKER SD. HMG-CoA reductase inhibition reduces high peripheral blood monocyte Toll-like receptor 4 expression in patients with heart failure (abstract). Circulation (2005) 112:II-638.
   Google Scholar
• WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7:687-692.
   PubMed Web of Science ®Google Scholar
• METHE H, KIM JO, KOFLER S, NABAUER M, WEIS M: Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler. Thromb. Vasc. Biol. (2005).
   PubMedGoogle Scholar
• BURDELYA LG, DIDONATO J, KRIVOKRYSENKO VI, GUROVA KV, KOGAN Y, KOMAROV PG, GUDKOV AV: NF-κB activating proteins as radioprotectants: derivatives of flagellin from Salmonella protect mice from hematopoietic and gastrointestinal radiation syndromes. International Workshop in Space Radiation Research (2004).
   Google Scholar
• HICKS L, SHI Y, MENA J, HAMMOND C, TOMIC Y, TOMAI YA, MILLER RL, SPANER DE: The effect of a Toll Receptor-7 agonist (S28690) on the immunogenicity of chronic lymphocytic leukemia cells. Blood (2006) 104:11.
   Web of Science ®Google Scholar
• HORSMANS Y, BERG T, DESAGER JP et al.: Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology (2005) 42:724-731.
   PubMed Web of Science ®Google Scholar
• TESTERMAN TL, GERSTER JF, IMBERTSON LM et al.: Cytokine induction by the immunomodulators imiquimod and S-27609. J. Leukoc. Biol. (1995) 58:365-372.
   PubMed Web of Science ®Google Scholar
• SAUDER DN, SMITH MH, SENTA-McMILLIAN T, SORIA I, MENG TC: Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob. Agents Chemother. (2003) 47:3846-3852.
   PubMed Web of Science ®Google Scholar
• SPRUANCE SL, TYRING SK, SMITH MH, MENG TC: Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J. Infect. Dis. (2001) 184:196-200.
   PubMed Web of Science ®Google Scholar
• KLINMAN DM: Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. (2004) 4:249-258.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, KANDIMALLA ER: Role of Toll-like receptors in antisense and siRNA. Nat. Biotechnol. (2004) 22:1533-1537.
   PubMed Web of Science ®Google Scholar
• ISHII KJ, GURSEL I, GURSEL M, KLINMAN DM: Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides. Curr. Opin. Mol. Ther. (2004) 6:166-174.
   PubMed Web of Science ®Google Scholar
• KRIEG AM: CpG motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol. (2002) 20:709-760.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, KANDIMALLA ER: Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol. Med. (2002) 8:114-121.
   PubMed Web of Science ®Google Scholar
• KANDIMALLA ER, YU D, AGRAWAL S: Towards optimal design of second-generation immunomodulatory oligonucleotides. Curr. Opin. Mol. Ther. (2002) 4:122-129.
   PubMed Web of Science ®Google Scholar
• KRIEG AM, EFLER SM, WITTPOTH M, AL ADHAMI MJ, DAVIS HL: Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. (2004) 27:460-471.
   PubMed Web of Science ®Google Scholar
• ROMAN M, SPIEGELBERG HL, BROIDE D, RAZ E: Gene immunization for allergic disorders. Springer Semin. Immunopathol. (1997) 19:223-232.
   PubMed Web of Science ®Google Scholar
• AGRAWAL DK, EDWAN J, KANDIMALLA ER et al.: Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. Int. Immunopharmacol. (2004) 4:127-138.
   PubMed Web of Science ®Google Scholar
• VOLLMER J: Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9. Expert Opin. Biol. Ther. (2005) 5:673-682.
   PubMed Web of Science ®Google Scholar
• BALDRIDGE JR, McGOWAN P, EVANS JT et al.: Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin. Biol. Ther. (2004) 4:1129-1138.
   PubMed Web of Science ®Google Scholar
• PAUL S: Technology evaluation: CpG-7909, Coley. Curr. Opin. Mol. Ther. (2003) 5:553-559.
   PubMed Web of Science ®Google Scholar
• HEIKENWALDER M, POLYMENIDOU M, JUNT T et al.: Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. (2004) 10:187-192.
   PubMed Web of Science ®Google Scholar
• SWITAJ T, LASEK W: Technology evaluation: HYB-2055, Hybridon. Curr. Opin. Mol. Ther. (2005) 7:376-383.
   PubMed Web of Science ®Google Scholar
• STOCKFLETH E, TREFZER U, GARCIA-BARTELS C et al.: The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br. J. Dermatol. (2003) 149(Suppl. 66):53-56.
   PubMed Web of Science ®Google Scholar
• JONES T: Resiquimod 3M. Curr. Opin. Investig. Drugs (2003) 4:214-218.
   PubMedGoogle Scholar
• METHE H, ZIMMER E, GRIMM C, NABAUER M, KOGLIN J: Evidence for a role of toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation. Transplantation (2004) 78:1324-1331.
   Google Scholar